Follicular Lymphoma (FL) Clinical Trial
Official title:
Evaluation of Peripheral Blood (PB) Immunophenotyping in the Detection of Bone Marrow Involvement in Cases of Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL) and Marginal Zone Lymphoma (MZL).
To determine whether peripheral blood flow cytometry can reduce or replace invasive bone marrow examinations in patients with slow growing lymphomas.
This study will determine whether peripheral blood flow cytometry can reduce or replace
invasive bone marrow examinations in patients with slow growing lymphomas.
Patients with certain types of slow growing (indolent) lymphomas, including the most common
sub-type, follicular lymphoma, require a bone marrow examination for staging of their
lymphoma. This provides prognostic information and can be important for planning treatment.
However, despite the use of local anaesthetic, and in some cases sedation, bone marrow
examinations can cause pain and discomfort to patients. Complications are rare but include
risk of bleeding, infection and even nerve damage.
Flow cytometry of peripheral blood samples can detect low levels of circulating lymphoma
cells. A previous study has demonstrated that detection of lymphoma cells by peripheral blood
flow cytometry has a good correlation with bone marrow involvement. This study will seek to
find if this correlation is evident in a larger, statistically significant patient cohort.
Depending on the study results, invasive and painful bone marrow procedures could potentially
be reduced or eliminated in patients with certain slow growing lymphomas. Patients diagnosed
with follicular lymphoma, mantle cell lymphoma or marginal zone lymphoma and being treated at
the Royal Marsden NHS Foundation Trust will be eligible for this study. Participation in the
study will require one peripheral blood sample to be taken before the patient's routine bone
marrow biopsy. The study is expected to last between 2 - 3 years for data collection of 108
samples.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06043011 -
Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms
|
||
| Active, not recruiting |
NCT04477486 -
Study to Assess Effect of Oral Venetoclax Tablet in Combination With Oral Ibrutinib Capsule on Best Overall Response of Complete Response in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma
|
Phase 2 | |
| Recruiting |
NCT05665530 -
A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib in Participants With R/R Hematologic Malignancies
|
Phase 1 | |
| Terminated |
NCT03571828 -
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma
|
Phase 1 | |
| Terminated |
NCT02914938 -
A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma
|
Phase 1 | |
| Active, not recruiting |
NCT04049513 -
ENABLE (Engaging Toll-like Receptor Signalling for B-cell Lymphoma Chimeric Antigen Receptor Therapy)
|
Phase 1 | |
| Recruiting |
NCT03869619 -
REal World Data in LYmphoma and Survival in Adults
|
||
| Active, not recruiting |
NCT04830137 -
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
|
Phase 1 | |
| Recruiting |
NCT03547115 -
A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML
|
Phase 1 | |
| Recruiting |
NCT04186520 -
CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT04767308 -
Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies
|
Early Phase 1 | |
| Active, not recruiting |
NCT02213926 -
An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma
|
Phase 2 | |
| Completed |
NCT03877055 -
A Study of Copanlisib and Ibrutinib in Mantle Cell Lymphoma
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06464861 -
Sequential Treatment of CD19 CARNK and 7x19 CAR-T in R/R B Cell Lymphoma
|
Phase 1 | |
| Enrolling by invitation |
NCT04488354 -
Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T
|
Phase 1 | |
| Recruiting |
NCT05720052 -
A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05716087 -
A Study of LP-168 in Participants With Relapse or Refractory Mantle Cell Lymphoma
|
Phase 2 | |
| Active, not recruiting |
NCT02362035 -
ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05406154 -
Ibrutinib Combined With Bendamustine and Rituximab in Newly Diagnosed Mantle Cell Lymphoma Patients Who Aged > 65 Years
|
||
| Recruiting |
NCT05951959 -
A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma
|
Phase 2 |